111 related articles for article (PubMed ID: 34519904)
1. Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.
Ma SJ; Serra LM; Yu B; Bartl AJ; Farrugia MK; Oladeru OT; Singh AK
Breast Cancer Res Treat; 2021 Oct; 189(3):737-745. PubMed ID: 34519904
[TBL] [Abstract][Full Text] [Related]
2. Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
Gill J; Yendamuri K; Chatterjee U; Yao S; Oladeru OT; Singh AK; Ma SJ
BMC Cancer; 2024 Apr; 24(1):461. PubMed ID: 38614979
[TBL] [Abstract][Full Text] [Related]
3. The Role of Oncotype DX
Pardo JA; Fan B; Mele A; Serres S; Valero MG; Emhoff I; Alapati A; James TA
Ann Surg Oncol; 2021 Mar; 28(3):1320-1325. PubMed ID: 33393046
[TBL] [Abstract][Full Text] [Related]
4. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
[TBL] [Abstract][Full Text] [Related]
5. Oncotype DX
Pease AM; Riba LA; Gruner RA; Tung NM; James TA
Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
[TBL] [Abstract][Full Text] [Related]
6. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
7. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
8. 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Parsons BM; Landercasper J; Smith AL; Go RS; Borgert AJ; Dietrich LL
Breast Cancer Res Treat; 2016 Sep; 159(2):315-26. PubMed ID: 27507245
[TBL] [Abstract][Full Text] [Related]
9. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Sella T; Gelber SI; Poorvu PD; Kim HJ; Dominici L; Guzman-Arocho YD; Collins L; Ruddy KJ; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Warner E; Snow C; Jakubowski DM; Russell CA; Winer EP; Rosenberg SM; Partridge AH
Breast Cancer Res Treat; 2021 Feb; 186(1):157-165. PubMed ID: 33150547
[TBL] [Abstract][Full Text] [Related]
10. Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
Taylor C; Meisel J; Foreman AJ; Russell C; Bandyopadhyay D; Deng X; Floyd L; Zelnak A; Bear H; O'Regan R
Breast Cancer Res Treat; 2023 May; 199(1):91-98. PubMed ID: 36897465
[TBL] [Abstract][Full Text] [Related]
11. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Chen J; Wu X; Christos PJ; Formenti S; Nagar H
Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
[TBL] [Abstract][Full Text] [Related]
12. Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.
AlSaleh K; Al Zahwahry H; Bounedjar A; Oukkal M; Saadeddine A; Mahfouf H; Bouzid K; Bensalem A; Filali T; Abdel-Razeq H; Larbaoui B; Kandil A; Abulkhair O; Al Foheidi M; Errihani H; Ghosn M; Abdel-Aziz N; Arafah M; Boussen H; Dabouz F; Rasool H; Bahadoor M; Ayari J; Kullab S; Nabholtz JM
JCO Glob Oncol; 2021 Jun; 7():811-819. PubMed ID: 34086481
[TBL] [Abstract][Full Text] [Related]
13. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Losk K; Freedman RA; Laws A; Kantor O; Mittendorf EA; Tan-Wasielewski Z; Trippa L; Lin NU; Winer EP; King TA
Breast Cancer Res Treat; 2021 Jan; 185(1):215-227. PubMed ID: 32939592
[TBL] [Abstract][Full Text] [Related]
14. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
[TBL] [Abstract][Full Text] [Related]
15. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
[TBL] [Abstract][Full Text] [Related]
16. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
17. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jasem J; Amini A; Rabinovitch R; Borges VF; Elias A; Fisher CM; Kabos P
J Clin Oncol; 2016 Jun; 34(17):1995-2002. PubMed ID: 27001563
[TBL] [Abstract][Full Text] [Related]
18. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
19. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS
Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886
[TBL] [Abstract][Full Text] [Related]
20. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
